MétaCan
Menu
← Back to cohort

The Economic Burden of Non-Diarrhea-Predominant IBS in Canada Based on the LOGIC Study

2009· article· en· W2977579399 on OpenAlexaffabout
Robert Balshaw, Pierre Paré, Olaf Heisel, M Barbeau

Bibliographic record

VenueThe American Journal of Gastroenterology · 2009
Typearticle
Languageen
FieldMedicine
TopicGastrointestinal motility and disorders
Canadian institutionsUniversité LavalNovartis (Canada)GDI Integrated Facility Services (Canada)Hôpital du Saint-Sacrement
Fundersnot available
KeywordsMedicineBloatingConstipationIrritable bowel syndromeDiarrheaMedical prescriptionAbdominal painIndirect costsInternal medicineNursing

Abstract

fetched live from OpenAlex

Purpose: To estimate the Canadian burden of illness costs of irritable bowel syndrome using data from the “Longitudinal Outcomes study of GastroIntestinal symptoms (abdominal pain, bloating, constipation) in Canada (LOGIC)”. Methods: The LOGIC study followed a total of 1556 subjects for 12 months. Patients were 18 years or older, with abdominal pain/discomfort (associated with altered bowel habits) and with one or more of the following symptoms: a) Abdominal pain/discomfort; b) Bloating c) Constipation or alternating between constipation and diarrhea. Patients with diarrhea-predominant IBS, those with organic disease of the GI tract, with evidence of structural abnormality of the GI tract or with conditions that could affect bowel transit were not eligible. Resource utilization under conditions of routine clinical care was collected for 12 months. Model-based estimates of Canada-wide costs assumed IBS prevalence of 13.1% and that only 40% of those with IBS will seek medical care. Resources were valued based on 2004 Canadian Dollars. Results: Subjects in LOGIC (i.e., representing those who sought medical care) spent $1963 per year on direct medical and medication costs, comprising $1180 (direct: physician & specialist and emergency room visits plus hospitalization and procedures), $380 for prescriptions and $403 for non-prescription medications for IBS. After accounting for those with IBS who do not seek medical care, this corresponds to an annual cost of $4.3 billion associated with the treatment of IBS in Canada ($2.0 billion direct costs, $636 million Rx, $1.7 billion non-Rx). Conclusion: These estimates of the economic burden based on the Canadian LOGIC study are derived from a population excluding diarrhea-predominant IBS and are higher than those reported for all IBS in the US, but are consistent with costs previously reported for IBS in Germany and earlier studies in Canada. The total costs to the Canadian health care system are estimated to be $4.3 billion annually for this debilitating, chronic condition. Disclosure: R Balshaw - Consultant to Novartis Pharmaceuticals Canada; P Pare - Consultant to Novartis Pharmaceuticals Canada; O Heisel - Consultant to Novartis Pharmaceuticals Canada; M Barbeau - Employee of Novartis Pharmaceuticals Canada. The LOGIC Study was sponsored by Novartis Pharmaceuticals Canada.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.054
Threshold uncertainty score0.389

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.005
Science and technology studies0.0010.001
Scholarly communication0.0020.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.243
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2009
Admission routes2
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicGastrointestinal motility and disorders→French-language works237,207→